Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Tonix Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics across CNS disorders, immunology, and infectious diseases. The company has no marketed products and operates as a pure R&D entity with multiple Phase 2/3 programs including TNX-102 SL for fibromyalgia, TNX-1300 for cocaine intoxication, and TNX-1800 (live virus vaccine platform). With minimal revenue ($0M TTM), extreme cash burn ($100M+ annually), and a 9.89x current ratio, the company is entirely dependent on clinical trial outcomes and equity financing to fund operations through potential FDA approvals in 2027-2028.
Tonix operates a classic biotech development model: raise equity capital, fund clinical trials through FDA approval, then monetize through product sales or licensing. The company has no pricing power until products reach market. Current strategy focuses on advancing multiple assets through Phase 2/3 trials to create option value across therapeutic areas. With 23.1% gross margin on negligible revenue, the company likely generates small amounts from research collaborations or government grants. The business model requires continuous capital raises (dilutive to shareholders) until achieving commercial-stage revenue, typically 18-36 months post-FDA approval for first meaningful cash generation.
Phase 2/3 clinical trial readouts for TNX-102 SL (fibromyalgia), TNX-1300 (cocaine intoxication), and other pipeline assets - binary events with 30-80% single-day moves typical
FDA regulatory decisions including IND clearances, Fast Track designations, and Breakthrough Therapy status for lead programs
Equity financing announcements and dilution concerns - with $100M+ annual burn and $20M market cap, dilution risk is extreme
Partnership or licensing deals that validate platform technology or provide non-dilutive funding
Competitive clinical data from rival CNS or immunology programs that shift probability-of-success assumptions
Binary clinical trial risk - single Phase 3 failure can eliminate 50-90% of market value overnight, with multiple programs creating portfolio risk but no diversification until commercial stage
Regulatory pathway uncertainty for novel mechanisms - FDA approval timelines for CNS and immunology assets can extend 12-24 months beyond initial estimates, exhausting cash runway
Equity dilution spiral - with $200M market cap and $100M+ annual burn, the company faces 50-80% dilution risk per financing round at current valuations, creating death spiral potential
Large pharma competition in CNS disorders (Eli Lilly, Biogen, Jazz Pharmaceuticals) with vastly superior capital resources and commercial infrastructure
Faster-moving competitors in fibromyalgia and pain management reaching market first, establishing treatment paradigms before Tonix can launch
Platform technology risk - live virus vaccine approach faces competition from mRNA and viral vector platforms with proven COVID-19 success
Extreme cash burn of $100M+ annually against $200M market cap creates existential financing risk within 12-18 months without successful capital raise
Negative ROE of -55.2% and ROA of -39.3% reflect value destruction, with shareholder equity declining rapidly through operating losses
Stock price decline of -70.3% over six months severely impairs ability to raise capital on favorable terms, forcing highly dilutive financings or reverse splits
low - Clinical-stage biotech operations are largely insulated from GDP fluctuations as R&D spending is committed years in advance and trial timelines are regulatory-driven, not economically driven. However, the company's ability to raise capital is highly sensitive to risk appetite in biotech equity markets, which correlates with broader economic conditions and tech/growth stock sentiment.
High interest rates negatively impact Tonix through two channels: (1) Valuation compression - biotech DCF models discount future cash flows at higher rates, disproportionately affecting pre-revenue companies with cash flows 5-10 years out; (2) Capital availability - rising rates reduce investor appetite for speculative, cash-burning growth stocks as safer fixed-income alternatives become attractive. The company's 9.89x current ratio provides temporary insulation, but sustained high rates make future equity raises more dilutive.
Minimal direct credit exposure with 0.00 debt/equity ratio. The company operates without traditional debt financing, relying entirely on equity markets. However, credit market conditions indirectly affect biotech venture funding and IPO markets, which influence the company's ability to raise follow-on capital.
momentum/speculative - Attracts high-risk biotech traders seeking 3-10x returns on binary clinical catalysts, not fundamental value investors. The -70.3% six-month return followed by +39.2% one-year return shows extreme volatility typical of clinical-stage names. With no revenue, negative margins, and total dependence on trial outcomes, this is pure speculation on FDA approval probability. Institutional ownership is likely minimal given market cap and risk profile.
high - Clinical-stage biotechs with <$500M market cap routinely experience 30-50% single-day moves on trial data. The stock's 6-month drawdown of -70.3% demonstrates extreme downside volatility. Implied volatility on options (if available) likely exceeds 100-150%. Beta to broader market is low, but idiosyncratic risk is extreme.
